DelveInsight’s, “Metastatic Pancreatic Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the Metastatic Pancreatic Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Metastatic Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Pancreatic Cancer pipeline products in this space.

 

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Pancreatic Cancer Pipeline Report to explore emerging therapies, key Metastatic Pancreatic Cancer Companies, and future Metastatic Pancreatic Cancer treatment landscapes @ Metastatic Pancreatic Cancer Pipeline Outlook Report

 

Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report

• In February 2025:- Erasca Inc.:- This is a Phase 1b/2, open-label, multicenter clinical study evaluating ERAS-007 in combination with other cancer therapies in study participants with GI malignancies. This study will serve as a platform study, allowing for evaluation of safety/tolerability and efficacy of ERAS-007 in combination with other cancer therapies. The study will initially commence with dose escalation of ERAS-007 administered in combination with encorafenib and cetuximab in study participants with metastatic colorectal cancer (CRC) harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation; and dose escalation of ERAS-007 administered in combination with palbociclib in study participants with metastatic CRC harboring Kirsten rat sarcoma (KRAS) or neuroblastoma rat sarcoma (NRAS) mutations and metastatic pancreatic adenocarcinoma with (PDAC) KRAS mutation.
• In January 2025:- Shanghai Yizhong Pharmaceutical Co., Ltd.-This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.
• In January 2025: – Verastem Inc.:- This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
• DelveInsight’s Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
• The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
• Promising Metastatic Pancreatic Cancer Therapies such as Parvovirus H-1 (H-1PV), Sunitinib, Napabucasin, Nab-paclitaxel, Gemcitabine, Dasatinib, mFOLFOX6, and others.

 

Discover how the Metastatic Pancreatic Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Pancreatic Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Pancreatic Cancer Clinical Trials and Studies

 

Metastatic Pancreatic Cancer Emerging Drugs Profile

• Motixafortide: BioLineRx

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

 

• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.

 

• HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

 

The Metastatic Pancreatic Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Pancreatic Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Pancreatic Cancer Treatment.
• Metastatic Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Pancreatic Cancer market.

 

Get a detailed analysis of the latest innovations in the Metastatic Pancreatic Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Pancreatic Cancer Unmet Needs

 

Metastatic Pancreatic Cancer Companies

Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.

 

Metastatic Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

 

Metastatic Pancreatic Cancer Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Pancreatic Cancer Therapies and key Metastatic Pancreatic Cancer Developments @ Metastatic Pancreatic Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Metastatic Pancreatic Cancer Pipeline Report

• Coverage- Global
• Metastatic Pancreatic Cancer Companies-Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
• Promising Metastatic Pancreatic Cancer Therapies– Parvovirus H-1 (H-1PV), Sunitinib, Napabucasin, Nab-paclitaxel, Gemcitabine, Dasatinib, mFOLFOX6, and others.
• Metastatic Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Which companies are leading the race in Metastatic Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Pancreatic Cancer Pipeline Report—access it now! @ Metastatic Pancreatic Cancer Emerging Drugs and Major Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Pancreatic Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Eleison Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MDB 401 B: Panbela Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SBP 101: Takeda Oncology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Pancreatic Cancer Key Companies
21. Metastatic Pancreatic Cancer Key Products
22. Metastatic Pancreatic Cancer- Unmet Needs
23. Metastatic Pancreatic Cancer- Market Drivers and Barriers
24. Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
25. Metastatic Pancreatic Cancer Analyst Views
26. Metastatic Pancreatic Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape